vs
BRUNSWICK CORP（BC）とUNITED THERAPEUTICS Corp（UTHR）の財務データ比較。上の社名をクリックして会社を切り替えられます
BRUNSWICK CORPの直近四半期売上が大きい（$1.3B vs $790.2M、UNITED THERAPEUTICS Corpの約1.7倍）。UNITED THERAPEUTICS Corpの純利益率が高く（46.1% vs 1.4%、差は44.7%）。BRUNSWICK CORPの前年同期比売上増加率が高い（15.5% vs 7.4%）。UNITED THERAPEUTICS Corpの直近四半期フリーキャッシュフローが多い（$173.3M vs $83.6M）。過去8四半期でUNITED THERAPEUTICS Corpの売上複合成長率が高い（8.0% vs -1.1%）
ブランズウィック・コーポレーションは1845年創業の米国企業で、多種多様な製品の開発・製造・販売を行っている。Mercury Marineをはじめとする複数のブランドを保有し、24カ国に1万3000人以上の従業員が在籍し、2024年の売上高は52億米ドル、世界本社はイリノイ州シカゴ北部郊外のメタワに所在する。
ユナイテッド・セラピューティクスは米国のバイオテクノロジー企業で、異種移植を含む臓器移植関連の医薬品や技術を開発しています。主力製品の多くは肺疾患治療や臓器製造分野向けで、メリーランド州とノースカロライナ州に2つの本社を置き、米国各地やカナダにも拠点を構えています。
BC vs UTHR — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $1.3B | $790.2M |
| 純利益 | $18.7M | $364.3M |
| 粗利率 | 23.1% | 86.9% |
| 営業利益率 | 3.1% | 45.1% |
| 純利益率 | 1.4% | 46.1% |
| 売上前年比 | 15.5% | 7.4% |
| 純利益前年比 | 122.7% | 20.9% |
| EPS（希薄化後） | $0.32 | $7.66 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $1.3B | $790.2M | ||
| Q3 25 | $1.4B | $799.5M | ||
| Q2 25 | $1.4B | $798.6M | ||
| Q1 25 | $1.2B | $794.4M | ||
| Q4 24 | $1.2B | $735.9M | ||
| Q3 24 | $1.3B | $748.9M | ||
| Q2 24 | $1.4B | $714.9M | ||
| Q1 24 | $1.4B | $677.7M |
| Q4 25 | $18.7M | $364.3M | ||
| Q3 25 | $-235.5M | $338.7M | ||
| Q2 25 | $59.3M | $309.5M | ||
| Q1 25 | $20.2M | $322.2M | ||
| Q4 24 | $-82.5M | $301.3M | ||
| Q3 24 | $44.6M | $309.1M | ||
| Q2 24 | $100.0M | $278.1M | ||
| Q1 24 | $68.0M | $306.6M |
| Q4 25 | 23.1% | 86.9% | ||
| Q3 25 | 25.8% | 87.4% | ||
| Q2 25 | 25.5% | 89.0% | ||
| Q1 25 | 24.9% | 88.4% | ||
| Q4 24 | 21.9% | 89.7% | ||
| Q3 24 | 26.2% | 88.9% | ||
| Q2 24 | 27.1% | 89.1% | ||
| Q1 24 | 27.4% | 89.2% |
| Q4 25 | 3.1% | 45.1% | ||
| Q3 25 | -17.8% | 48.6% | ||
| Q2 25 | 7.1% | 45.6% | ||
| Q1 25 | 4.6% | 48.2% | ||
| Q4 24 | -4.8% | 48.6% | ||
| Q3 24 | 7.7% | 45.8% | ||
| Q2 24 | 11.0% | 44.7% | ||
| Q1 24 | 8.1% | 52.6% |
| Q4 25 | 1.4% | 46.1% | ||
| Q3 25 | -17.3% | 42.4% | ||
| Q2 25 | 4.1% | 38.8% | ||
| Q1 25 | 1.7% | 40.6% | ||
| Q4 24 | -7.1% | 40.9% | ||
| Q3 24 | 3.5% | 41.3% | ||
| Q2 24 | 6.9% | 38.9% | ||
| Q1 24 | 5.0% | 45.2% |
| Q4 25 | $0.32 | $7.66 | ||
| Q3 25 | $-3.59 | $7.16 | ||
| Q2 25 | $0.89 | $6.41 | ||
| Q1 25 | $0.30 | $6.63 | ||
| Q4 24 | $-1.21 | $6.23 | ||
| Q3 24 | $0.67 | $6.39 | ||
| Q2 24 | $1.48 | $5.85 | ||
| Q1 24 | $0.99 | $6.17 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $256.8M | $2.9B |
| 総負債低いほど良い | $2.1B | — |
| 株主資本純資産 | $1.6B | $7.1B |
| 総資産 | $5.3B | $7.9B |
| 負債/資本比率低いほどレバレッジが低い | 1.30× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $256.8M | $2.9B | ||
| Q3 25 | $297.7M | $2.8B | ||
| Q2 25 | $315.7M | $3.0B | ||
| Q1 25 | $286.7M | $3.3B | ||
| Q4 24 | $269.0M | $3.3B | ||
| Q3 24 | $284.1M | $3.3B | ||
| Q2 24 | $494.5M | $3.0B | ||
| Q1 24 | $548.4M | $2.7B |
| Q4 25 | $2.1B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $2.4B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $1.6B | $7.1B | ||
| Q3 25 | $1.6B | $6.6B | ||
| Q2 25 | $1.9B | $7.2B | ||
| Q1 25 | $1.9B | $6.8B | ||
| Q4 24 | $1.9B | $6.4B | ||
| Q3 24 | $2.0B | $6.1B | ||
| Q2 24 | $2.0B | $5.7B | ||
| Q1 24 | $2.0B | $5.3B |
| Q4 25 | $5.3B | $7.9B | ||
| Q3 25 | $5.4B | $7.4B | ||
| Q2 25 | $5.8B | $7.9B | ||
| Q1 25 | $5.9B | $7.7B | ||
| Q4 24 | $5.7B | $7.4B | ||
| Q3 24 | $6.0B | $7.1B | ||
| Q2 24 | $6.4B | $6.7B | ||
| Q1 24 | $6.5B | $6.5B |
| Q4 25 | 1.30× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.25× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $132.9M | $346.2M |
| フリーキャッシュフロー営業CF - 設備投資 | $83.6M | $173.3M |
| FCFマージンFCF / 売上 | 6.3% | 21.9% |
| 設備投資強度設備投資 / 売上 | 3.7% | 21.9% |
| キャッシュ転換率営業CF / 純利益 | 7.11× | 0.95× |
| 直近12ヶ月FCF直近4四半期 | $396.3M | $1.0B |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $132.9M | $346.2M | ||
| Q3 25 | $140.4M | $562.1M | ||
| Q2 25 | $316.2M | $191.7M | ||
| Q1 25 | $-27.4M | $461.2M | ||
| Q4 24 | $306.4M | $341.2M | ||
| Q3 24 | $67.4M | $377.2M | ||
| Q2 24 | $211.0M | $232.2M | ||
| Q1 24 | $-153.4M | $376.5M |
| Q4 25 | $83.6M | $173.3M | ||
| Q3 25 | $106.5M | $351.6M | ||
| Q2 25 | $271.3M | $129.5M | ||
| Q1 25 | $-65.1M | $386.3M | ||
| Q4 24 | $276.1M | $254.5M | ||
| Q3 24 | $31.4M | $300.7M | ||
| Q2 24 | $163.9M | $187.1M | ||
| Q1 24 | $-207.4M | $338.3M |
| Q4 25 | 6.3% | 21.9% | ||
| Q3 25 | 7.8% | 44.0% | ||
| Q2 25 | 18.7% | 16.2% | ||
| Q1 25 | -5.3% | 48.6% | ||
| Q4 24 | 23.9% | 34.6% | ||
| Q3 24 | 2.5% | 40.2% | ||
| Q2 24 | 11.4% | 26.2% | ||
| Q1 24 | -15.2% | 49.9% |
| Q4 25 | 3.7% | 21.9% | ||
| Q3 25 | 2.5% | 26.3% | ||
| Q2 25 | 3.1% | 7.8% | ||
| Q1 25 | 3.1% | 9.4% | ||
| Q4 24 | 2.6% | 11.8% | ||
| Q3 24 | 2.8% | 10.2% | ||
| Q2 24 | 3.3% | 6.3% | ||
| Q1 24 | 4.0% | 5.6% |
| Q4 25 | 7.11× | 0.95× | ||
| Q3 25 | — | 1.66× | ||
| Q2 25 | 5.33× | 0.62× | ||
| Q1 25 | -1.36× | 1.43× | ||
| Q4 24 | — | 1.13× | ||
| Q3 24 | 1.51× | 1.22× | ||
| Q2 24 | 2.11× | 0.83× | ||
| Q1 24 | -2.26× | 1.23× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
BC
| Engine Partsand Accessories | $532.4M | 40% |
| Navico Group | $452.9M | 34% |
| Recreational Fiberglass Boats | $111.6M | 8% |
| Saltwater Fishing Boats | $85.7M | 6% |
| Controls Riggingand Propellers | $78.3M | 6% |
| Business Acceleration | $48.1M | 4% |
| Sterndrive Engine | $32.6M | 2% |
UTHR
| Tyvaso DPI | $338.6M | 43% |
| Remodulin | $128.0M | 16% |
| Nebulized Tyvaso | $125.7M | 16% |
| Orenitram | $121.2M | 15% |
| Unituxin | $62.3M | 8% |
| Adcirca | $7.8M | 1% |
| Other | $6.6M | 1% |
